Erratum: Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer (Prostate Cancer and Prostatic Diseases (2010) 13 (168-172) DOI: 10.1038/pcan.2010.4);Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 2, 2010, Pages 168-172

  Gacci, M ^a   Corona, G ^b   Apolone, A ^c   Lanciotti, M ^a   Tosi, N ^a   Giancane, S ^a   Masieri, L ^a   Serni, S ^a   Maggi, M ^a   Carini, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Free testosterone; Hypogonadism; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE; ARTICLE; BODY MASS; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PENIS ERECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RANK SUM TEST; SEXUAL BEHAVIOR; SEXUAL FUNCTION; STUDENT T TEST; TESTOSTERONE BLOOD LEVEL; URINARY TRACT FUNCTION;

EID: 77952550441     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.13     Document Type: Erratum

References (30)

1. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-320.
2. Miller NL, Bissonette EA, Bahnson R, Wilson J, Theodorescu D. Impact of a novel neoadjuvant and adjuvant hormonedeprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer 2003;97:1203-1210. (Pubitemid 36237305)
3. Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008;54:785-793.
4. Wright J, Lin D, Cowan J, Carroll P, Litwin M, the caPSURE Investigators. Quality of life in young men after radical prostatectomy. Prost Cancer Prost Dis 2008;11:67-73.
5. Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006;42:1083-1092.
6. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269-1277.
7. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007;99(Suppl 1):19-22.
8. Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 2008;6:46-52.
9. Hwang TI, Lo HC, Tsai TF, Chiou HY. Association among hypogonadism, quality of life and erectile dysfunction in middle-aged and aged male in Taiwan. Int J Impot Res 2007;19:69-75.
10. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-541.
11. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-922.
12. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007;34:549-553.
13. Rhoden EL, Averbeck MA, Teloken PE. Androgen replacement in men undergoing treatment for prostate cancer. J Sex Med 2008;5:2202-2208.
14. Gacci M, Livi L, Paiar F, Detti B, Litwin MS, Bartoletti R et al. Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index. Urology 2005;66:338-343.
15. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged 5 version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-326.
16. Gould DC, Feneley MR, Kirby RS. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy. BJU Int 2006;98:1-4.
17. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91:3850-3856.
18. Corona G, Boddi V, Lotti F, Gacci M, Carini M, De Vita G et al. The relationship of testosterone to PSA in men with sexual dysfunction. J Sex Med 2010;7:284-292.
19. Mikhail N. Does testosterone have a role in erectile function? Am J Med 2006;119:373-382.
20. Martínez-Jabaloyas JM, Queipo-Zaragozá A, Pastor-Hernández F, Gil-Salom M, Chuan-Nuez P. Testosterone levels in men with erectile dysfunction. BJU Int 2006;97:1278-1283.
21. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006;68:1263-1267.
22. Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009;104:486-489.
23. Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009;6(Suppl 3):234-238.
24. Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30:880-888.
25. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-2263.
26. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-947.
27. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-1868.
28. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-1029.
29. Gacci M, Ierardi A, Delle Rose A, Tazzioli S, Scapaticci E, Filippi S et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo controlled pilot study. J Sex Med 2010;7:234-243.
30. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane K, Vignozzi L et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7:59-69.